GASTRIN COMPOUND FOR DIABETES TREATMENT
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 7, 2010
app pub date -
Feb 29, 2008
filing date -
Mar 2, 2007
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The invention relates to compositions and methods for the prevention or treatment of diabetes, comprising a therapeutically effective amount of at least one gastrin compound ie gastrin G1. The gastrin compound provides beneficial effects comprising the control of haemoglobin AIc (HbA1c), fasting blood glucose, glucose levels or insulin levels. The subjects which are treated with the compositions and methods of the invention are selected based on baseline HbA1c levels or based on existing treatment with a glucose lowering agent with or without an insulin sensitivity enhancer, in particular, a metformin with or without a thiazolidinedione. The use of a gastrin compound for decreasing HbA1c levels in a diabetic subject is also proposed.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully